Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Millennium Pharmacon International Tbk Receipts from Customers Chart
PT Millennium Pharmacon International Tbk Annual Data
PT Millennium Pharmacon International Tbk Receipts from Customers Calculation
A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Receipts from Customers represents payment received from customers in the direct cash flow method.
Receipts from Customers for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp4,201,931 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Receipts from Customers of Rp4,201,931 Mil mean?
PT Millennium Pharmacon International Tbk (ISX:SDPC) has a Receipts from Customers of Rp4,201,931 Mil as of Jun. 2026. Receipts from Customers represents payment received from customers in the direct cash flow method. View historical data for PT Millennium Pharmacon International Tbk and its competitors.
Is PT Millennium Pharmacon International Tbk's Receipts from Customers too high?
PT Millennium Pharmacon International Tbk's current Receipts from Customers is Rp4,201,931 Mil. Overall, PT Millennium Pharmacon International Tbk has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PT Millennium Pharmacon International Tbk's Receipts from Customers compare to MCK and COR?
PT Millennium Pharmacon International Tbk's Receipts from Customers of Rp4,201,931 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receipts from Customers for a Medical Distribution company?
A good Receipts from Customers depends on the Medical Distribution industry context. However, Receipts from Customers should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receipts from Customers mean?
A high Receipts from Customers can signal that a stock is expensive relative to its fundamentals. Receipts from Customers represents payment received from customers in the direct cash flow method. View historical data for PT Millennium Pharmacon International Tbk and its competitors. PT Millennium Pharmacon International Tbk's current Receipts from Customers is Rp4,201,931 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Millennium Pharmacon International Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk (ISX:SDPC) is currently considered Modestly Overvalued. The stock's GF Value™ is Rp170.29, compared to a current price of Rp190.00 — trading 11.6% above its estimated fair value. The current Receipts from Customers is Rp4,201,931 Mil. PT Millennium Pharmacon International Tbk's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receipts from Customers calculated?
Receipts from Customers is calculated from a company's financial statements. For PT Millennium Pharmacon International Tbk (ISX:SDPC), the current Receipts from Customers is Rp4,201,931 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Millennium Pharmacon International Tbk (ISX:SDPC) Overvalued in 2026?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk stock appears to be overvalued.
The current stock price of Rp190.00 is trading 11.6% above its estimated GF Value™ of Rp170.29.
GuruFocus considers PT Millennium Pharmacon International Tbk to be Modestly Overvalued.
Key valuation signals for ISX:SDPC:
Receipts from Customers: Rp4,201,931 Mil
GF Value™: Rp170.29 vs. price of Rp190.00 (11.6% above fair value)
No single metric tells the full story. See the ISX:SDPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressJl. Sultan Iskandar Muda No 18/Jl. Bungur No. 1, Crown Bungur Arteri Lantai 2-4, Kel. Kebayoran Lama Selatan, Kec. Kebayoran Lama, South Jakarta, Jakarta, IDN, 12240
PT Millennium Pharmacon International Tbk is engaged in distributing medicines, food supplements, and medical disposables. The group's operating segments are Prescription medicine, Non-prescription medicine, Medical Disposables, and others, of which the majority of revenue is derived from the Prescription Medicine segment. The company's geographical segments are Jawa, Sumatra, Kalimantan, Sulawesi, and Bali & Lombok.
79GF Score
Get the complete analysis for ISX:SDPC
Receipts from Customers is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SDPC has been successfully added to your 
